Cellular Context Matters
Cellular context matters in guiding treatment decisions. The wide range of clinical response to vemurafenib between patients with a melanoma and patients with a colorectal carcinoma with identical BRAF V600E mutation is an illustrative example. This large contrast in pharmacologic sensitivity to BRAF V600E inhibition is caused by a difference in feedback activation of EGFR. Melanoma cells, which express low levels of EGFR, cannot circumvent the growth inhibitory effect of BRAF inhibitors. By contrast, colorectal cells upregulate EGFR in response to BRAF inhibition, resulting in EGFR-driven tumors. Therefore, combinatorial drug therapy of EGFR and BRAF inhibition in BRAF V600E mutant colon cancers might be more effective. 1 Although our understanding of the impact of cell context on the signaling perturbations induced by mutations is growing, too little is known about distinctions between cells from benign and malignant lesions. For example, BRAF V600E mutations are detectable in both be-nign nevi and melanomas. However, in melanomas BRAF V600E cooperates with PTEN loss to induce metastasis. Ultimately deciphering the impact of cellular context of mutations found in benign and malignant tumors will also be crucial for optimal cancer treatment strategies. 2 
Clonal Diversity
Genetically diverse cell populations within a tumor are related by descent through branched evolutionary patterns. This genealogy, conceptually modeled with a phylogenetic tree, is created through stochastically acquired mutations and subsequent clonal expansion of individual cells. There is a great variation in degree of complexity (clonal diversity) and phylogenetic tree topology between cancers. Cancers with minimal genomic complexity such as small-cell hypercalcemic ovarian carcinomas have a stereotypical diagnostic mutation and few other genomic abnormalities, providing limited scope for divergence. 3 Cancers with more complex genomes such as high-grade serous carcinomas of the ovary show multiple clones, which are related by descent but which show extensive genetic divergence. 4 In such cancers, mutations may be present only in small subpopulations of cells and many are absent in specific, spatially distinct samples. However, initiating mutations such as loss of function TP53 mutations in high-grade serous ovarian cancers will usually be present in every cell. Knowledge of clonal diversity in a tumor's evolutionary pattern can be important for guiding optimal cancer treatment decisions. For example, early clonal mutations at the root of the phylogeny may be optimal targets from a genomic perspective; however, other considerations such as the type of mutation (activating or truncating) strongly influence target selection.
Treatment Efficacy Barriers Due to Resistance Mutations
Intrinsic or acquired drug resistance due to resistance mutations is a major barrier for effective cancer treatment. A cancer cell can have different escape routes to acquired resistance including (1) acquiring a mutation of the drug target itself, (2) activation of the pathway downstream of the targeted blockade, (3) activation of a parallel pathway, and (4) hyperactivation of the inhibited pathway (reviewed in the article by Bernards 5 ). Knowledge and identification of drug targets whose inactivation is only effective after a second mutation (synthetic lethality) may also help to develop combinatorial drug therapy to target multiple driver events or provide pre-dictive biomarkers to avoid treatment efficacy barriers due to known resistance mutations. 6
Mutation Activation Status Confirmed?
The first step to determine if a mutation has a functional role in the tumorigenic process would be to distinguish "driver" mutations from "passengers." Another challenge in distinguishing drivers from passengers is that a driver gene contains a driver gene mutation but can also contain multiple passenger gene mutations. Bioinformatics approaches that can predict the impact of mutations on the encoded gene and pathways will be essential for the translation of genomic data into useful clinical applications. So far, most methodologies to predict the functional effect of mutations have relied on the DNA sequence alone. Now that DNA mutation data and gene expression levels are available through collaborative efforts like The Cancer Genome Atlas, some algorithms are taking advantage to identify likely driver mutations by virtue of their effect on messenger RNA expression to predict the functional effect of the mutation (eg, DriverNet). 7 In addition, pathway activation status could be assessed by a variety of proteomic approaches including reversephase protein arrays.
Conclusions
Although the identification and use of somatic mutations to inform cancer treatment decisions is now standard of care, the accuracy of clinical decisions may be improved if mutation data are contextualized through consideration of the cellular and genomic milieu in which the mutations are found.
